Medios cuts 2026 outlook, sees sales at €2-2.12 billion and EBITDA pre at €88-92 million

• Medios cut 2026 guidance on July 28, targeting sales of EUR 2-2.12 billion versus EUR 2.1-2.16 billion previously.
• EBITDA pre forecast lowered to EUR 88-92 million from EUR 94-102 million, reflecting weaker expected H2 profitability.
• Price pressure in high-margin medicines expected to persist, weighing Pharmaceutical Supply margins despite H1 sales growth of 8.4% to EUR 1.07 billion.
• New German law effective July 30 excludes cannabis flowers from reimbursement, pressuring H2 revenues and margins in the cannabis business.
• International Business outlook weakened by recent profitability pressure, partly offset by expected margin gains in Patient-Specific Therapies from cost actions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medios AG published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.